Corbus Pharmaceuticals Holdings (CRBP) Net Cash Flow (2013 - 2025)

Corbus Pharmaceuticals Holdings has reported Net Cash Flow for 13 years, with the latest figure at $6.9 million in Q3 2025.

• On a quarterly basis, Net Cash Flow rose 262.77% year-over-year to $6.9 million in Q3 2025; TTM through Sep 2025 was $7.6 million, a 7.51% decrease from a year earlier, with the FY2024 full-year figure at $3.5 million, up 205.95% from the prior year.
• Net Cash Flow was $6.9 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from $1.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $32.0 million in Q1 2022, with the low at -$31.3 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$3.1 million, with a median of $1.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow sank 1383.47% in 2022, then surged 835.59% in 2024.
• Over 5 years, Net Cash Flow stood at -$12.1 million in 2021, then soared by 137.64% to $4.6 million in 2022, then plunged by 45.71% to $2.5 million in 2023, then plunged by 189.9% to -$2.2 million in 2024, then jumped by 411.87% to $6.9 million in 2025.
• The last three Net Cash Flow figures came in at $6.9 million (Q3 2025), $1.1 million (Q2 2025), and $1.7 million (Q1 2025), per Business Quant data.